Table 1 Clinical features
Items | Patients (N = 54) |
|---|---|
Age (years), mean ± SD | 62.0 ± 9.7 |
Gender, no. (%) | |
Male | 29 (53.7) |
Female | 25 (46.3) |
Tumor location, no. (%) | |
Head of pancreas | 17 (31.5) |
Body of pancreas | 17 (31.5) |
Cauda of pancreas | 29 (53.7) |
Liver metastasis, no. (%) | 54 (100.0) |
Single | 9 (16.7) |
Multiple | 45 (83.3) |
Extrahepatic metastasis, no. (%) | |
Intra-abdomen | 34 (63.0) |
Lymph gland | 4 (7.4) |
Skeleton | 6 (11.1) |
Lung | 3 (5.6) |
No extrahepatic metastases | 12 (22.2) |
Number of extrahepatic metastases, no. (%) | |
0 | 12 (22.2) |
1 | 18 (33.3) |
2 | 14 (25.9) |
3 | 8 (14.8) |
4 | 1 (1.9) |
5 | 1 (1.9) |
Size of liver metastasis (cm), median (IQR) | 2.7 (1.5–3.5) |
Tumor markers, median (IQR) | |
CA199 (U/mL) | 1000.0 (59.7–1000.0) |
CA125 (U/mL) | 78.2 (33.3–227.9) |
CEA (ng/mL) | 14.4 (4.9–67.0) |
Treatment, No. (%) | |
AG | 33 (61.1) |
Other GEM-based regimens | 33 (61.1) |
Folfirinox | 5 (9.3) |
Others | 14 (25.9) |
Liver stiffness, median (IQR) | |
EM of liver metastasis | 57.9 (43.3–83.5) |
EM of peripheral liver tissue | 7.5 (6.3–10.4) |
Relative EM | 7.8 (4.8–10.7) |